CL2014002393A1 - Moléculas de unión a ang2; composicion farmaceutica que las contiene; y sus usos terapeuticos. - Google Patents

Moléculas de unión a ang2; composicion farmaceutica que las contiene; y sus usos terapeuticos.

Info

Publication number
CL2014002393A1
CL2014002393A1 CL2014002393A CL2014002393A CL2014002393A1 CL 2014002393 A1 CL2014002393 A1 CL 2014002393A1 CL 2014002393 A CL2014002393 A CL 2014002393A CL 2014002393 A CL2014002393 A CL 2014002393A CL 2014002393 A1 CL2014002393 A1 CL 2014002393A1
Authority
CL
Chile
Prior art keywords
pharmaceutical composition
binding molecules
therapeutic uses
ang2 binding
ang2
Prior art date
Application number
CL2014002393A
Other languages
English (en)
Spanish (es)
Inventor
Pascal Merchiers
Andreas Gschwind
Rene Georg Ott
Joachim Boucneau
Eric Borges
Erik Depla
Mari-Ange Buyse
Frederik Stevenaert
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48190468&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014002393(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2014002393A1 publication Critical patent/CL2014002393A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CL2014002393A 2012-03-30 2014-09-10 Moléculas de unión a ang2; composicion farmaceutica que las contiene; y sus usos terapeuticos. CL2014002393A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12162615 2012-03-30

Publications (1)

Publication Number Publication Date
CL2014002393A1 true CL2014002393A1 (es) 2015-01-23

Family

ID=48190468

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014002393A CL2014002393A1 (es) 2012-03-30 2014-09-10 Moléculas de unión a ang2; composicion farmaceutica que las contiene; y sus usos terapeuticos.

Country Status (27)

Country Link
US (5) US20130259859A1 (cg-RX-API-DMAC10.html)
EP (1) EP2831111B1 (cg-RX-API-DMAC10.html)
JP (1) JP5970734B2 (cg-RX-API-DMAC10.html)
KR (1) KR102020255B1 (cg-RX-API-DMAC10.html)
CN (1) CN104321344B (cg-RX-API-DMAC10.html)
AU (1) AU2013241769B2 (cg-RX-API-DMAC10.html)
BR (1) BR112014023415B1 (cg-RX-API-DMAC10.html)
CA (1) CA2865464C (cg-RX-API-DMAC10.html)
CL (1) CL2014002393A1 (cg-RX-API-DMAC10.html)
CY (1) CY1122007T1 (cg-RX-API-DMAC10.html)
DK (1) DK2831111T3 (cg-RX-API-DMAC10.html)
EA (1) EA031182B1 (cg-RX-API-DMAC10.html)
ES (1) ES2729165T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20190817T1 (cg-RX-API-DMAC10.html)
HU (1) HUE044263T2 (cg-RX-API-DMAC10.html)
IL (1) IL234234B (cg-RX-API-DMAC10.html)
IN (1) IN2014DN06904A (cg-RX-API-DMAC10.html)
LT (1) LT2831111T (cg-RX-API-DMAC10.html)
MX (1) MX350248B (cg-RX-API-DMAC10.html)
NZ (1) NZ628584A (cg-RX-API-DMAC10.html)
PH (1) PH12014502179A1 (cg-RX-API-DMAC10.html)
PL (1) PL2831111T3 (cg-RX-API-DMAC10.html)
PT (1) PT2831111T (cg-RX-API-DMAC10.html)
RS (1) RS58732B1 (cg-RX-API-DMAC10.html)
SI (1) SI2831111T1 (cg-RX-API-DMAC10.html)
TR (1) TR201908638T4 (cg-RX-API-DMAC10.html)
WO (1) WO2013144266A1 (cg-RX-API-DMAC10.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
WO2016057367A1 (en) 2014-10-06 2016-04-14 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
CA2964470A1 (en) 2014-10-17 2016-04-21 Amgen Inc. Antibodies directed to angiopoietin-1 and angiopoietin-2 for ocular therapies
EP3277317A1 (en) * 2015-03-31 2018-02-07 VHsquared Limited Peptide construct having a protease-cleavable linker
RU2749674C2 (ru) * 2015-07-29 2021-06-16 Аллерган, Инк. Антитела против ang-2, содержащие только тяжелую цепь
US20190300967A1 (en) * 2016-10-13 2019-10-03 Dana-Farber Cancer Institute, Inc. Compositions and methods for predicting response and resistance to ctla4 blockade in melanoma using a gene expression signature
KR102143132B1 (ko) * 2016-12-26 2020-08-10 기초과학연구원 항 Ang2 항체를 포함하는 안구질환 예방 및 치료용 조성물
CN109071656B (zh) 2017-01-05 2021-05-18 璟尚生物制药公司 检查点调节物拮抗剂
CN110691790A (zh) * 2017-06-02 2020-01-14 勃林格殷格翰国际有限公司 抗癌联合治疗
CN108659130B (zh) * 2018-05-28 2021-09-10 长春力太生物技术有限公司 一种抗癌胚抗原纳米抗体及其应用
EP3813864A4 (en) 2018-06-29 2022-07-20 Gensun Biopharma Inc. Antitumor antagonists
CA3131250A1 (en) * 2019-02-25 2020-09-03 Pharmabcine Inc. Anti-ang2 antibody and use thereof
US20220185875A1 (en) * 2019-03-18 2022-06-16 Jiangsu Hengrui Medicine Co., Ltd. Bispecific antibody specifically bound to vegf and ang2
WO2020263312A1 (en) 2019-06-28 2020-12-30 Gensun Biopharma, Inc. ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFβ1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
CN115151263A (zh) * 2020-03-03 2022-10-04 爱普济德生物技术有限公司 适体和其用途
CN111875706B (zh) * 2020-07-16 2021-03-30 广州康盛生物科技股份有限公司 一种抗人IgE蛋白的单域抗体及其应用
US20220389120A1 (en) 2021-06-03 2022-12-08 Gensun Biopharma Inc. Multispecific antagonists
IL311318A (en) * 2021-09-10 2024-05-01 Soter Biopharma Pte Ltd Anti-Ang2 antibody, its preparation method and its application
CN119894924A (zh) 2022-09-28 2025-04-25 科兴生物制药股份有限公司 能够识别ang-2的抗体或抗原结合片段和同时识别vegf和ang-2的双抗
CN115819592A (zh) * 2022-12-27 2023-03-21 上海医药集团生物治疗技术有限公司 靶向ror1的抗原结合蛋白
WO2025117641A2 (en) * 2023-12-01 2025-06-05 Tavotek Biotherapeutics (Hong Kong) Limited ANTIBODIES TARGETING DISEASE ASSOCIATED ANTIGEN AND γδ T CELL RECEPTORS AND USES THEREOF
WO2025137089A1 (en) * 2023-12-19 2025-06-26 Beam Therapeutics Inc. Cd19-binding polypeptides, compositions comprising the same, and methods for use thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1589107E (pt) 1992-08-21 2010-03-29 Univ Bruxelles Imunoglobulinas desprovidas de cadeias leves
US5643755A (en) 1994-10-07 1997-07-01 Regeneron Pharmaceuticals Inc. Nucleic acid encoding tie-2 ligand
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
CA2433877C (en) 2001-01-17 2014-11-18 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2003002609A2 (en) 2001-06-28 2003-01-09 Domantis Limited Dual-specific ligand and its use
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
EP1558645B1 (en) 2002-11-08 2011-07-27 Ablynx N.V. Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
EP2301967A3 (en) 2002-11-08 2011-07-13 Ablynx N.V. Single domain antibodies for nasal administration
AU2003283136A1 (en) 2003-11-07 2005-05-26 Ablynx N.V. Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
US20050284249A1 (en) 2004-06-29 2005-12-29 Arnone David F Worm type gear mover assembly
BRPI0518151A2 (pt) 2004-10-13 2009-06-16 Ablynx Nv polipetìdeos contra amiloide-beta, ácido nucléico que codifica tal polipetìdeo, composição compreendendo tal polipetìdeo, método para produzir um polipetìdeo e uso do mesmo
ATE521638T1 (de) 2004-12-21 2011-09-15 Medimmune Ltd Gegen angiopoietin-2 gerichtete antikörper und anwendungen davon
CA2608770C (en) 2005-05-18 2017-05-30 Ablynx Nv Improved nanobodies against tumor necrosis factor-alpha
JP2009539870A (ja) 2006-06-06 2009-11-19 ジェネンテック・インコーポレーテッド 血管発生の調節ための組成物および方法
WO2008020079A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
JP2010518839A (ja) 2007-02-21 2010-06-03 アブリンクス エン．ヴェー． 血管内皮増殖因子に指向性を有するアミノ酸配列、及び過度の及び／もしくは病的な血管形成又は血管新生を特徴とする症状及び疾患を治療するためにこれを含むポリペプチド
US20110091462A1 (en) 2008-03-05 2011-04-21 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making and uses thereof
US9193780B2 (en) * 2008-06-05 2015-11-24 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
EP2364328A2 (en) * 2008-12-10 2011-09-14 Ablynx NV Amino acid sequences directed against the angiopoietin/tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US20130078247A1 (en) * 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2

Also Published As

Publication number Publication date
IN2014DN06904A (cg-RX-API-DMAC10.html) 2015-05-15
US20130259859A1 (en) 2013-10-03
US20170107281A1 (en) 2017-04-20
CY1122007T1 (el) 2020-10-14
WO2013144266A1 (en) 2013-10-03
KR102020255B1 (ko) 2019-09-10
HRP20190817T1 (hr) 2019-06-28
BR112014023415A2 (pt) 2017-07-11
US20200207845A1 (en) 2020-07-02
EA031182B1 (ru) 2018-11-30
US20190135907A1 (en) 2019-05-09
US20230203146A1 (en) 2023-06-29
RS58732B1 (sr) 2019-06-28
TR201908638T4 (tr) 2019-07-22
LT2831111T (lt) 2019-05-10
PL2831111T3 (pl) 2019-09-30
NZ628584A (en) 2016-04-29
HUE044263T2 (hu) 2019-10-28
PH12014502179B1 (en) 2014-12-10
DK2831111T3 (en) 2019-04-29
MX2014011171A (es) 2015-03-06
CN104321344B (zh) 2017-11-21
SI2831111T1 (sl) 2019-06-28
JP5970734B2 (ja) 2016-08-17
EP2831111A1 (en) 2015-02-04
CA2865464A1 (en) 2013-10-03
KR20140146606A (ko) 2014-12-26
AU2013241769B2 (en) 2017-05-11
EP2831111B1 (en) 2019-03-20
JP2015516805A (ja) 2015-06-18
IL234234B (en) 2020-06-30
MX350248B (es) 2017-08-31
EA201401065A1 (ru) 2015-03-31
CA2865464C (en) 2022-07-12
ES2729165T3 (es) 2019-10-30
PH12014502179A1 (en) 2014-12-10
CN104321344A (zh) 2015-01-28
AU2013241769A1 (en) 2014-08-28
PT2831111T (pt) 2019-05-31
BR112014023415B1 (pt) 2022-04-12

Similar Documents

Publication Publication Date Title
CL2014002393A1 (es) Moléculas de unión a ang2; composicion farmaceutica que las contiene; y sus usos terapeuticos.
CL2014003136A1 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos; composicion farmaceutica que los contiene y usos.
CL2014002954A1 (es) Composicion farmaceutica que contiene anticuerpos anti-il-23p19 y sus usos.
DK3608325T3 (da) Polycykliske-carbamoylpyridonforbindelser og deres farmaceutiske anvendelse
CO7061078A2 (es) Compuestos de enediino, conjugados de los mismos y sus usos y metodos
BR112015002790A2 (pt) anticorpos asgpr e usos dos mesmos.
DK3121164T3 (da) Sulfamoylpyrrolamidderivater og anvendelse deraf som medikamenter til behandling af hepatitis b
BR112015001596A2 (pt) composição para o tratamento de hiperlipidemia que compreende oxintomodulina.
EP2896039A4 (en) IMPROVING THE PHONETIC DEBATE
DK3181128T3 (da) Farmaceutisk nilotinib-sammensætning
HUE046964T2 (hu) Kombinált gyógyászati készítmény
DK2818482T3 (da) Farmaceutisk sammensætning til behandling af cancer
DK2914965T3 (da) Aflukker til biologiske mikroobjekter
DK2824114T3 (da) Farmaceutisk sammensætning til behandling af cancer
CO7051008A2 (es) Moléculas de unión específicas para her3 y usos de las mismas
CL2014002019A1 (es) Anticuerpos anti - asic1; composicion farmaceutica que lo comprende y usos de los mismos.
BR112016018062A2 (pt) compostos terapêuticos, composição farmacêutica e usos
DK2914630T3 (da) Hidtil ukendte antigen-bindende proteiner og deres anvendelse som adresseringsprodukt til behandling af kræft
CL2015000762A1 (es) Combinaciones farmacéuticas que comprenden aglutinantes duales de angiopoyetina-2/dll4 y agentes anti-vegf
DK2897594T3 (da) Farmaceutisk sammensætning
DK3258938T3 (da) Phenothiazinanaloger som mitokondrie terapeutiske midler
DK2809669T3 (da) Kondenserede pyrroldicarboxamider og deres anvendelse som farmaceutika
EP2813521A4 (en) CURABLE COMPOSITION AND APPLICATION THEREOF
CL2014002951A1 (es) (r)-nifuratel; formulacion farmaceutica que lo contiene; y proceso para fabricar (r)-nifuratel y (s)-nifuratel.
EP2838488A4 (en) DRUGS DONORS